Prostate Cancer Diagnostic Test Could Prevent Over or Under Treatment

By distinguishing low- and intermediate-risk patients, Oncotype DX is predicted to avoid over- and under-treatment of prostate cancer patients.

Genomic Health, Inc. (Nasdaq: GHDX) today announced results from two studies of the Oncotype DX® prostate cancer test demonstrating its value in low- and intermediate-risk prostate cancer to enable physicians and patients to avoid over- and under-treatment of the disease. Both studies will be presented today, December 3, at the Society of Urologic Oncology (SUO) Annual Meeting, in Bethesda, Md.

Results from the latest clinical validation study, published in European Urology this month online, show that the Oncotype DX test predicts near- and longer-term outcomes in a racially diverse group of men with clinically localized prostate cancer. The analyses, conducted in collaboration with the Uniformed Services University of the Health Sciences' Center for Prostate Disease Research (CPDR), reconfirmed the biopsy-based Oncotype DX prostate cancer test as a predictor of whether adverse pathology would be found if the prostate were removed by surgery. Additionally, for the first time, the Oncotype DX prostate cancer test was validated as a strong independent predictor of biochemical recurrence, which is a rise in PSA following surgery. Furthermore, the study, in which 20 percent of patients were African-American men, demonstrated that Oncotype DX is similarly predictive of outcomes in both Caucasian and African-American men.

Link to the article on CNBC: http://cnb.cx/1BepSwb